See What HealthDay Can Do For You
Contact Us

Resistance to Second-Line TB Drugs Is Common Globally

Nearly half resistant to at least one drug; 6.7 percent have extensively drug-resistant TB

THURSDAY, Aug. 30 (HealthDay News) -- Nearly half of patients with tuberculosis in eight countries show resistance to at least one second-line drug, with previous treatment with second-line drugs strongly associated with resistance to these drugs and with extensively drug-resistant (XDR) tuberculosis, according to a study published online Aug. 30 in The Lancet.

Tracy Dalton, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined resistance to second-line antituberculosis drugs among 1,278 patients from Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea, and Thailand. To identify risk factors for resistance to second-line drugs and XDR tuberculosis, the results were compared with clinical and epidemiological data.

The researchers found that 43.7 percent of patients showed resistance to at least one second-line drug, with 20.0 percent showing resistance to at least one second-line injectable drug and 12.9 percent to at least one fluoroquinolone. A total of 6.7 percent of patients had XDR, which ranged from 0.8 to 15.2 percent across study sites. The strongest risk factor for resistance to second-line drugs was previous treatment with second-line drugs, which was linked with more than a four-fold increase in the risk of XDR tuberculosis. Women more frequently experienced fluoroquinolone resistance and XDR tuberculosis, compared with men. Resistance to second-line injectables was correlated with unemployment, alcohol abuse, and smoking.

"Previous treatment with second-line drugs is a strong, consistent risk factor for resistance to these drugs, including XDR tuberculosis," the authors write. "Representative drug-susceptibility results could guide in-country policies for laboratory capacity and diagnostic strategies."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.